IL6 and rheumatoid arthritis: The RNA-seq analyses suggested that baricitinib treatment changed the gene expression profiles of DRG in the CAIA mice more closely to the control group than the celecoxib treatment via modulating several signalling pathways associated with RA, including IL-6/JAK/STAT3.